Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP385 phase 2b study in adults with moderate to severe essential tremor
2020-002463-61Phase 2Completed
- Sponsor
- Cavion
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of suvecaltamide in essential tremor (ET) (4 arms), sponsored by Cavion. Primary endpoint: Change from baseline to Week 12 in TETRAS composite outcome score. Started Dec 2021; status: completed.
02
Drugs
suvecaltamide
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on 2020-002463-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002463-61.